Trastuzumab, a humanized anti-HER-2 monoclonal antibody, has been approved for treatment of patients with breast cancers that overexpress the human epidermal growth factor receptor-2 (HER-2) protein or that exhibit ErbB2 gene amplification9. The gene discussed is ERBB2; the disease is breast carcinoma.